Latest total liabilities for EVAX: $10M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), EVAX shows a total liabilities of $10M. That compares with $15M in the prior-year period — down 30.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, EVAX's total liabilities is now $10M (was $15M) — a 30.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Evaxion Biotech A/S is outperforming or lagging.
Tracking EVAX's total liabilities over time shows whether Evaxion Biotech A/S is scaling, shrinking, or reshaping that part of the business. The current reading is $10M That compares with $15M in the prior-year period — down 30.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total liabilities page, Stockcircle has Evaxion Biotech A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $10M) with ownership activity and broader fundamentals.
Evaxion Biotech A/S's total liabilities is $10M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.